Back to top

Image: Bigstock

Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?

Read MoreHide Full Article

Aurora Cannabis Inc. (ACB - Free Report) is scheduled to report first-quarter fiscal 2022 results on Nov 9, after the closing bell.

In the last-reported quarter, the company’s loss of 21 cents was narrower than the Zacks Consensus Estimate of a loss of 22 cents. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on one occasion and missed in the other three, delivering a negative earnings surprise of 62.67%, on average.

Let’s see how things have shaped up prior to this announcement.

Factors to Note

On its fiscal 2021 fourth-quarter earnings call in September, Aurora Cannabis confirmed that it had won three tender lots in France, which included all available dry flower lots. The company had delivered its first shipment in August and confirmed delivering an $8 million cannabis shipment in July in Israel as part of the company’s supply agreement with Cantek Global Ltd. These activities are likely to have significantly boosted the company’s fiscal 2022 first-quarter revenues.

Over the past few months, the company has been registering growth in the Canadian adult-recreational segment, which management believes to have resulted from its focus on superior quality as well as potency and higher-margin products. This trend is likely to have continued in the fiscal first quarter as well thereby, driving up Aurora Cannabis’ revenues.

Aurora Cannabis Inc. Price and EPS Surprise

Aurora Cannabis Inc. Price and EPS Surprise

Aurora Cannabis Inc. price-eps-surprise | Aurora Cannabis Inc. Quote

Further, new store openings and rising consumer demand are likely to have driven revenues in the adult-recreational segment.

During the last-reported quarter, the company recorded growth in its San Rafael '71 cannabis brand. This trend is likely to have continued in the to-be-reported quarter due to the introduction of additional premium products and Aurora Cannabis’ focus on innovation throughout all categories. We are also hopeful of a continued recovery in the company’s international medical revenues, which have been improving over the past few months due to a favorable country mix.

In June, Aurora Cannabis had launched three new proprietary cultivars under its premium adult-use cannabis brand San Rafael '71 — Stonefruit Sunset, Lemon Rocket and Driftwood Diesel. Revenues from the sale of these are likely to have contributed to the company’s to-be-reported quarter’s top line.

The Estimate Picture

For first-quarter fiscal 2022, the Zacks Consensus Estimate of $48.9 million for total revenues implies a decline of 3.9% from the prior-year quarter’s reported figure.

The consensus estimate for the bottom line is pegged at a loss of 18 cents per share, indicating an improvement of 71.9% from the prior-year period’s reported number.

What Our Model Suggests

Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) along with a positive Earnings ESP has higher chances of beating estimates. However, this is not the case here.

Earnings ESP: Aurora Cannabis has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: The company currently carries a Zacks Rank #3.

Stocks Worth a Look

Here are a few medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.

Insulet Corporation (PODD - Free Report) has an Earnings ESP of +15.79% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Henry Schein, Inc. (HSIC - Free Report) has an Earnings ESP of +0.16% and a Zacks Rank of 2, at present.

Natera, Inc. (NTRA - Free Report) has an Earnings ESP of +3.75% and is a Zacks #2 Ranked stock.